Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components

Table 7 One-way sensitivity analyses (Incremental Cost-Effectiveness Ratio expressed in €/QALY; discounted at 3 %)

Value	V/H	V/A	A/H
Baseline	16,192.40	8690.13	12,694.89
Discount rate
Low: 0 %	9136.23	4899.12	6528.41
High: 6 %	18,887.19	10,127.14	15,888.91
Generic Substitution
Cheapest generics	30,021.13	21,881.33	12,870.17
Marginal price (further price decrease −75 %)	41,707.74	51,015.44	17,685.29
Health resources cost
50 % decrease	16,188.30	8766.81	12,518.28
50 % increase	16,202.98	8620.55	12,875.81
Price estimation based on alternative sickness fund coverage
Deterministic	30,021.13	15,609.78	11,069.45
Probabilistic (mean)	26,105.42	18,295.66	11,298.31
Age group
40 years	12,976.54	7133.45	16,440.77
60 years	19,162.85	10,037.84	11,961.30
70 years	23,846.40	11,883.61	9960.84
Clinical characteristics
All patients diabetics	16,477.38	8711.76	13,137.42
Prior CVD	15,342.43	7966.95	11,985.83

Abbreviations: V valsartan, H hydrochlorothiazide, A amlodipine, CVD cardiovascular disease

ISSN: 1478-7547